Pancreatic cancer is exceptionally aggressive with no long-term effective therapy. Current interventional approaches, including surgery, radiation and/or chemotherapy, have done little to quell the mortality associated with this malignancy. Subtraction hybridization identified a cancer-specific apoptosis-inducing cytokine gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), with a broad range of selective antitumor activity in diverse cancers both in vitro and in vivo in nude mice and recently in patients with advanced carcinomas and melanomas. Unlike most neoplasms, pancreatic cancers display innate resistance to mda-7/ IL-24-induced apoptosis, which correlates with a diminished capacity to convert mda-7/IL-24 mRNA into protein. We presently demonstrate that this translational block can be reversed by treatment with agents that elevate reactive oxygen species (ROS). Induction of apoptosis in vitro and suppression of tumorigenesis in vivo in nude mice are induced in pancreatic cancers, irrespective of the status of their K-ras gene, only when tumor cells simultaneously express mda-7/IL-24 and are treated with a ROS-inducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophene (NSC656240 (NSC)). In pancreatic cancer cells constitutively expressing mda-7/IL-24 mRNA, a single treatment with arsenic trioxide, HPR or NSC656240 induces apoptosis, which correlates with production of MDA-7/IL-24 protein. The specificity of this action is documented by the ability of ROS inhibitors, including Nacetyl-L-cysteine and Tiron, to block this killing effect. Of potential clinical significance, similar treatment of normal cells does not elicit significant changes in growth nor does it induce apoptosis. Analysis of signal transduction changes in pancreatic carcinoma cells infected with Ad.mda-7 in combination with a ROS-inducer indicate that cell death correlates with modulation of discrete cassettes of multiple signaling pathways in a pancreatic cancer cell-specific manner, supporting global signaling dysregulation as a potential mediator of apoptosis induction. These findings suggest a promising combinatorial approach for safely promoting cell death in pancreatic tumors that provides a rational framework for developingIntroduction Adenocarcinoma of the pancreas is a particularly lethal cancer and the fourth leading cause of cancer-related death in the United States (McKenna and Eatock, 2003) . Approximately 30 000 Americans are predicted to develop pancreatic cancer in 2004 with overall survival rate for all stages being less than 1% at 5 years with the majority of patients dying within 1 year (Kulke, 2002) . Despite these abysmal statistics and the increase in incidence over the past several decades, the molecular and biochemical determinants of pancreatic cancer remain enigmas and no effective therapeutic regimens significantly ameliorate the clinical course or prognosis of this disease (Bardeesy and DePinho, 2002; Jaffee et al., 2002; Kern et al., 2002) .
Employing subtraction hybridization in combination with induction of terminal differentiation in human melanoma cells, genes associated with cancer growth control, tumorigenesis and differentiation continue to be identified and cloned (Jiang and Fisher, 1993; Huang et al., 1999a, b; Jiang et al., 2000) . One mda-gene of particular significance, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) (Jiang et al., 1995) , selectively induces growth suppression and apoptosis in a broad spectrum of human cancers, without eliciting apparent deleterious effects in normal cells (Jiang et al., 1995 (Jiang et al., , 1996 Su et al., 1998; Madireddi et al., 2000; Saeki et al., 2000; Mhashilkar et al., 2001; Lebedeva et al., 2002 Lebedeva et al., , 2004 Fisher et al., 2003) . One exception to this apparent universal cancer-specific action is pancreatic cancer, which displays remarkable resistance to mda-7/IL-24, when applied by transfection using an expression vector construct or when transduced by means of a replication incompetent adenovirus (Ad.mda-7) (Su et al., 2001 ). In the case of mutant Kras pancreatic carcinomas, which represent the vast majority of tumors (B85-95%) (Bardeesy and DePinho, 2002; Jaffee et al., 2002; Kern et al., 2002) , ablating K-ras expression using antisense phosphorothioate oligonucleotides specifically targeting the K-ras gene, sensitizes tumor cells to Ad.mda-7-induced apoptosis (Su et al., 2001) . In contrast, blocking K-ras gene expression in wild-type K-ras BxPC-3 cells does not sensitize these cells to Ad.mda-7, suggesting additional defects may contribute to resistance to mda-7/IL-24 in this tumor cell (Su et al., 2001) .
Previous studies document that reactive oxygen species (ROS) contribute to the ability of mda-7/IL-24 to synergize with radiation to kill renal carcinoma cells and it plays a significant role in the ability of Ad.mda-7 to induce apoptosis selectively in prostate tumor cells . Based on these considerations, we have now tested the hypothesis that altering mitochondrial function using ROS-inducers might provide a means of sensitizing normally resistant pancreatic cancer cells to the cancer-specific apoptosis-inducing activity of Ad.mda-7. This hypothesis has been confirmed, since treatment with established ROS inducers, arsenic trioxide (ARS) and N-(4-hydroxyphenyl) retinamide (HPR), or a differentiation-associated ROS inducing dithiophene NSC656240 (NSC) (Jing et al., 1999; Wu et al., 2001; Simeone et al., 2002; Lebedeva et al., 2003b) sensitizes both mutant and wildtype K-ras pancreatic cancer cells to mda-7/IL-24-induced apoptosis. Induction of apoptosis correlates with a reversal in the translational block in MDA-7 protein production (Su et al., 2001) . Moreover, in pancreatic carcinoma cells constitutively expressing mda-7/IL-24 mRNA, treatment solely with ARS, HPR or NSC induces apoptosis. The cell death-promoting effect of Ad.mda-7 is abrogated when cells are simultaneously treated with the antioxidants N-acetyl-L-cysteine (NAC) or Tiron. In contrast, as observed previously in normal renal and human prostate epithelial cells, mda-7/IL-24 plus a ROS-inducer does not alter the growth or survival of normal immortal melanocytes or astrocytes. Studies designed to define specific signal transduction pathways associated with Ad.mda-7 plus ROS inducer-promoted apoptosis in pancreatic carcinoma cells highlight the complexity of changes associated with combination treatment that occurs in a compound-specific and pancreatic cancer cell-specific manner. These findings support the hypothesis of global signaling dysfunction involving changes in cassettes of specific signal transduction pathways as potential mediators of apoptosis induction by combinatorial treatment with Ad.mda-7 and the different ROSinducing compounds. Of potential clinical relevance, resistance to mda-7 in pancreatic carcinoma cells is not irreversible and by appropriate treatment can be circumvented. In this context, by appropriate pharmacological manipulation it may be possible to more effectively use mda-7/IL-24 to treat specific cancers, such as pancreatic carcinomas.
Results
Ad.mda-7 plus ROS-inducers cause growth suppression and a loss in viability in mutant and wild-type K-ras pancreatic cancer cells in vitro Infection of mutant K-ras (PANC-1 or MIA PaCa-2) or wild-type K-ras (BxPC-3) pancreatic carcinoma cells with 100 plaque-forming units (pfu)/cell of Ad.mda-7 does not alter growth or reduce viability (Figure 1) . Similarly, treatment with ARS (1 mM), HPR (3 mM) or NSC (200 nM), at potentially physiologically achievable levels, does not significantly modify proliferation or reduce survival in pancreatic cancer cells. In contrast, combination treatment with Ad.mda-7 plus ARS, HPR or NSC decreases growth and viability in both mutant and wild-type K-ras pancreatic carcinoma cells. Further support for the efficacy of the combination of mda-7/ IL-24 and ROS-inducers in suppressing growth in pancreatic cancer cells is provided by studies employing PANC-1 clones, PANC M8 and PANC M14, and MIA PaCa-2 clones, PaCa M1 and PaCa M2, stably expressing mda-7/IL-24 mRNA (Figure 2a ). Despite stable expression of mda-7/IL-24 mRNA (Figure 2b ), these clones of pancreatic cancer cells do not contain detectable MDA-7/IL-24 protein (data not shown). In these mda-7/IL-24 mRNA expressing clones, treatment with only ARS, HPR or NSC, at concentrations not affecting growth of parental PANC-1 or MIA PaCa-2 cells induces growth suppression and a loss of viability (Figure 2a) . A potential role of ROS-production in mediating these effects in mda-7/IL-24 mRNA-expressing clones is suggested by the discovery that antioxidants, NAC and Tiron, prevent reductions in viability in these ROS inducer-treated pancreatic tumor cells (Figure 2a ). In contrast, under similar experimental conditions in normal SV-40-immortallized melanocytes (FM516-SV) and normal H-TERT-immortalized primary human fetal astrocytes (PHFA-Im) (Figure 1 ) growth and survival were not altered, providing support for the specificity of this approach in the context of pancreatic cancer cells.
Ad.mda-7 plus ROS-inducers promote apoptosis in both mutant and wild-type K-ras pancreatic cancer cells Based on previous studies in pancreatic tumor cells (Su et al., 2001 ), a potential mechanism by which the combination of Ad.mda-7 plus a ROS-inducer decreases viability is by induction of apoptosis. To test this Strategy to promote apoptosis in pancreatic cancer cells IV Lebedeva et al possibility, we determined the effect of infection with Ad.mda-7 (or Ad.vec) alone or in combination with a ROS-inducer (ARS, HPR or NSC) on Annexin V staining, an early indicator of induction of apoptosis. In PANC-1, MIA PaCa-2 and BxPC-3 cells, virus infection or treatment with a ROS-inducer plus Ad.vec did not enhance Annexin V staining, whereas the combination of Ad.mda-7 plus a ROS-inducer produced apoptosis ( Figure 3 ). This effect was ablated when cells were simultaneously exposed to the antioxidant NAC. In the case of PANC M8 and PaCa M1 cell clones stably expressing mda-7/IL-24 mRNA (Figure 4) Lebedeva et al., 2003b) . In this context, a potential pathway by which the combination of Ad.mda-7 and ARS or HPR treatment, as well as exposure to NSC , induce their profound effects on pancreatic cancer cells could involve a synergistic induction in ROS. When treated with ARS, HPR or NSC, the level of ROS was increased in Ad.mda-7-infected PANC-1, MIA PaCa-2 and BxPC-3 cells, but not in normal FM516-SV or PHFA-Im cells (Table 1 and data not shown). This effect was reduced or extinguished when combination treated cells were also exposed to NAC (Table 1 ). In the case of PANC M8 and PaCa M1 clones, treatment with ARS, HPR or NSC in the absence of Ad.mda-7-infection enhanced the production of ROS (Table 1 ). In these genetically modified cells, treatment with ARS, HPR or NSC in combination with NAC ablated the induction of ROS. These data provide support for the hypothesis that the combination of Ad.mda-7 plus ROS-inducers promotes apoptosis selectively in pancreatic cancer cells by augmenting the production of ROS, thereby promulgating programmed cell death. Moreover, they suggest that presence of mda-7/IL-24 mRNA in pancreatic cancer cells following stable transformation with an mda-7/IL-24 expression plasmid renders these cells sensitive to a single treatment with a ROS-inducer, thereby resulting in apoptosis.
MDA-7 protein production in pancreatic cancer cells directly correlates with induction of apoptosis by combination treatment with Ad.mda-7 plus a ROS-inducer
Previous studies confirmed that Ad.mda-7 infection of pancreatic cancer cells resulted in high levels of mda-7/ IL-24 RNA, without significant protein production Figure 1 Ad.mda-7 expression combined with a ROS-inducer selectively inhibits growth in pancreatic cancer cells. The indicated cell type was infected with Ad.mda-7 or Ad.vec (100 pfu/cell) and untreated or treated with a ROS-inducer (ARS, 1 mM; NSC, 200 nM; HPR, 3 mM) alone or with an antioxidant (NAC, 5 mM and Tiron, 0.1 mM). After 3 days, MTT assays were performed as described in Materials and methods. Antioxidants were added 2 h prior to infection. Results are the average from at least three experiments7s.e.
Strategy to promote apoptosis in pancreatic cancer cells IV Lebedeva et al (Su et al., 2001) . In contrast, when K-ras expression was ablated in mutant K-ras pancreatic carcinoma cells by treatment with antisense K-ras phosphorothioate oligonucleotides, this translational block was reversed resulting in MDA-7 protein and induction of apoptosis (Su et al., 2001) . Similarly, treatment of PANC-1, MIA PaCa-2 or BxPC-3 cells with a ROS-inducer, including NSC, ARS or HPR, and infection with Ad.mda-7 resulted in production of MDA-7 protein, whereas infection or treatment with these agents alone did not induce apoptosis or result in significant MDA-7 protein ( Figure 5 and data not shown). A role for ROSinduction in this process is supported by the ability of NAC to block MDA-7 protein production. In the case of PANC M8 and PaCa M1, a single treatment with a ROS-inducer resulted in induction of apoptosis and production of MDA-7 protein ( Figure 5 and data not shown). Uniquely, the combination of a ROS-inducer and Ad.mda-7 was also able to induce MDA-7 protein and apoptosis in the context of BxPC-3 cells, a process also prevented by simultaneous treatment with NAC ( Figure 5 ). Interestingly, treatment of pancreatic carcinoma cells with ROS inducers alone or in combination with Ad.mda-7 did not change K-ras protein levels (data not shown), suggesting K-ras-independent induction of apoptosis following combination treatment. In total, these results argue that reversion of the mda-7/IL-24 translational block is a critical event associated with the ability of the combination of ROS plus Ad.mda-7 to selectively induce apoptosis in pancreatic cancer cells and this effect occurs independent of the K-ras status of these cells.
Ad.mda-7 plus ROS-inducers differentially modify multiple signal transduction pathways in pancreatic cancer cells
Previous studies by several groups have linked the toxicities of Ad.mda-7 and GST-MDA-7 to the Figure 2 Single treatment with a ROS-inducer selectively inhibits growth in pancreatic cancer cells stably expressing mda-7 mRNA. (a) Parental or stable mda-7/IL-24 mRNA expressing PANC-1 pancreatic cancer clones, PANC M8 and PANC M14, or MIA PaCa-2 pancreatic cancer clones, PaCa M1 and PaCa M2, were treated with the indicated agents and analysed as described in Figure 1 . Results for both Panels a and b are the average from at least three experiments7s.e. (b) Production of mda-7/IL-24 mRNA in clones of PANC-1 and MIA PaCa-2 after transfection with an mda-7/IL-24 expressing vector and selection of hygromycin-resistant clones. Total RNA was isolated as described and analysed by Northern blotting. Blots were probed with a random-primed [ 32 P]mda-7 cDNA probe and exposed for autoradiography. After the blots were stripped they were reprobed with a random-primed [ 32 P]gapdh cDNA probe Strategy to promote apoptosis in pancreatic cancer cells IV Lebedeva et al activation of diverse signaling pathways, including ERK1/2, p38 and/or the JNK1/2/3, in a cell-typedependent manner (Kawabe et al., 2002; Sarkar et al., 2002b; Su et al., 2003; Yacoub et al., 2003a Yacoub et al., , b, 2004 Sauane et al., 2004) . It has also been argued that Ad.mda-7 in specific situations can suppress AKT activity, which correlates with cell killing (Mhashilkar et al., 2003) . Based on these considerations, we investigated whether ROS-induced cell death of PANC-1, MIA PaCa-2, BxPC-3 cells correlates with alterations in the activities of specific signaling pathways. Cells were infected with Ad.vec or Ad.mda-7 and were treated 3 h later with a ROS inducer (ARS, NSC or HPR) at nontoxic concentrations, which were previously determined by dose-response viability assays. At 24 h postinfection, protein lysates were collected and analysed by immunoblotting for changes in activation, as monitored by enhanced phosphorylation, of JNK1/2, ERK1/2, ERK5 and p38 MAPK protein kinases with corresponding phospho-specific antibodies and antibodies recognizing total kinase levels as described in Materials and methods. After autoradiography, films were scanned and quantitated using the ImageJ program. Ratios between the levels of phosphorylated and total protein amount for each protein kinase were calculated and normalized to the corresponding ratio in untreated cells (Tables 2a-d) . As an example of our primary data, we present analysis of ERK1/2 phosphorylation and total ERK1/2 expression by immunoblotting ( Figure 6 ). Compared to infection with Ad.vec, Ad.mda-7 infection slightly upregulated JNK1/2, ERK1/2 and ERK5 phosphorylation in PANC-1 cells, modestly downregulated p38 MAPK and ERK5 function in BxPC-3 cells and ERK1/2 activity in MIA PaCa-2 cells (Tables 2a-d , Figure 6 ). Initial studies examined the activities of signaling pathways that have been generally linked to cytotoxic responses in tumor cells. In PANC-1 and MIA PaCa-2 cells treated with Ad.mda-7 plus NSC, the activities of p38 and JNK1/2 were significantly enhanced compared to treatment with the individual agents alone, which correlated with loss of viability; in BxPC-3 cells the same combined treatment caused activation of JNK1/2, but not p38, which was also associated with cell killing (Tables 2a and b) . p38 was activated in all three pancreatic cancer cell lines treated with Ad.mda-7 plus ARS; however, JNK activation under these conditions was observed only in MIA PaCa-2 and BxPC-3 cells. As a single agent HPR treatment slightly activated JNK1/2 and inhibited p38 signaling in all of the cancer cells studied (Tables 2a and b) . The combination of HPR treatment with Ad.mda-7 infection significantly enhanced JNK1/2 activity in PANC-1 and BxPC-3 cells, and slightly activated p38 in MIA PaCa-2 cells. In apoptosis-resistant immortalized human fetal astrocytes, however, treatment with ROS inducers alone or in combination with Ad.mda-7 did not change p38 activity and only HPR weakly increased JNK1/2 activity (Tables 2a and b) .
Compared to untreated cells, ERK1/2 activity was slightly enhanced in PANC-1 cells after 24 h under the majority of treatment conditions, except with the combination of Ad.mda-7 plus NSC, where it was decreased almost 2.5-fold ( Figure 6 and Table 2c ). In MIA PaCa-2 cells, treatment with ARS, HPR or NSC modestly downregulated ERK1/2 activity, 24 h after exposure ( Figure 6 and Table 2c ). Combination of these Strategy to promote apoptosis in pancreatic cancer cells IV Lebedeva et al agents with Ad.mda-7 further depressed ERK1/2 activity. At 24 h after exposure to NSC or HPR, ERK1/2 activity was reduced in BxPC-3 cells, and this effect was modestly amplified upon combination treatment of Ad.mda-7 with these agents. ARS treatment alone or in combination with Ad.mda-7 did not modulate ERK1/2 activity in BxPC-3 cells. In immortalized fetal human astrocytes, only an insignificant increase in ERK1/2 activity was apparent relative to controls with any of the single or multiple treatment protocols. Studies of ERK5 phosphorylation demonstrated that all treatments marginally modulated the activity of this kinase (Table 2d) . Collectively, these studies demonstrate cell type specific differences in the signaling responses of different pancreatic cancer cells following infection with Ad.mda-7 and treatment with NSC, ARS or HPR, showing perturbation of multiple signal transduction pathways rather than a single signal pathway change associating with induction of apoptosis in combination treated pancreatic cancer cells.
Ad.mda-7 plus ROS-inducers cause growth suppression and a loss in viability in pancreatic cancer cells in vivo
To determine if the in vitro pancreatic cancer growth inhibitory effect of the combination of Ad.mda-7 plus ROS-inducer translates into in vivo antitumor activity, experiments were performed with PANC-1 cells in nude mice. Cells were untreated, treated with a ROSinducer (1 mM of ARS), and uninfected or infected with 100 pfu/cell of Ad.vec or Ad.mda-7, and 24 h later they were injected into nude mice. Control untreated PANC-1 cells formed aggressive, rapidly growing tumors, which were first apparent by 7-days postinjection. Similarly, PANC-1 cells infected with Ad.vec or Ad.mda-7, or treated singly with ARS, developed tumors with similar kinetics and growth properties. In contrast, tumor formation in PANC-1 cells was significantly inhibited (Po0.05) by the combination of treatment with a ROSinducer and infection with Ad.mda-7 (Figure 7) . These experiments confirm that the synergy observed in combinatorial treated pancreatic cancer cells in vitro extends to in vivo antipancreatic tumor activity and the effects induced by this combinatorial approach are irreversible.
Discussion
Although scrutinized comprehensively, effective therapies for pancreatic cancer have remained elusive. This disease is complex with genetic changes evident in several genes, either activation or inactivation, during tumor development and progression (Bardeesy and DePinho, 2002; Jaffee et al., 2002; Kern et al., 2002; Kulke, 2002; McKenna and Eatock, 2003) . Frequent genetic modifications in pancreatic carcinomas include activation of the K-ras oncogene (B85-95%) and inactivation of the p16/RB1 (>90%), p53 (75%) and Cells were treated with the indicated agents for 24 h, and protein lysates were prepared, as described in Materials and methods. Samples of 50 mg of total protein were run on 12% SDS-PAGE, transferred onto PVDF membrane and stained with phosphospecific pJNK, pp38MAPK, pERK1/2 or pERK5 antibodies and then with corresponding antibodies for total kinases. Kinase phosphorylation (activity) was quantitatively analysed via laser-scanning densitometry using NIH ImageJ software. Ratios between the levels of phosphorylated and total kinases were determined and normalized against the corresponding ratio for Ad.vec-treated cells. Bold numbers represent statistically significant changes occurring in multiple experiments (t-test, Po0.05). Concentrations of ROS inducers used: NSC, 0.2 mM; ARS, 1 mM; HPR, 3 mM DPC4 (55%) tumor suppressor genes (Bardeesy and DePinho, 2002; Jaffee et al., 2002; Kern et al., 2002) . These findings indicate significant defects in 'molecular circuitry' in pancreatic carcinoma cells and highlight the intricacy of this cancer. Moreover, this spectrum of complex alterations may underlie the aggressiveness and inherent resistance of this neoplasm to conventional therapies, including chemotherapy and radiation. Recent studies document that a combinatorial approach employing the cancer-specific apoptosis-inducing cytokine gene mda-7/IL-24 (Jiang et al., 1995; Fisher et al., 2003; Lebedeva et al., 2004) with selective inhibition of K-ras gene expression provides an effective means of inducing apoptosis in pancreatic cancer cells containing a mutated K-ras gene (Su et al., 2001) . However, this combination does not suppress growth or induce cell death in BxPC-3 pancreatic cancer cells with a wild-type K-ras genotype (Su et al., 2001) . A unique attribute of pancreatic cancer cells infected with a replication incompetent adenovirus expressing mda-7/ IL-24, Ad.mda-7 (Su et al., 1998) , is the expression of abundant quantities of gene-specific mRNA without significant protein (Su et al., 2001 ). This translational block in conversion of mda-7/IL-24-specific mRNA into protein is reversed in mutant K-ras pancreatic cancer cells by ablating expression of the K-ras gene using antisense approaches (including antisense phosphorothioate oligonucleotides or an antisense expression vector) (Su et al., 2001 ). An ability to facilitate the translation of specific mRNAs by inhibiting ras has been documented in a recent study, demonstrating that inhibiting ras expression results in an increase of specific mRNAs that associate with actively translating polysomes, thereby producing protein (Rajasekhar et al., 2003) . In the present study, we demonstrate that agents that promote ROS production, including ARS, HPR and NSC, also nullify the mda-7/IL-24 mRNA translational block, resulting in MDA-7/IL-24 protein, growth suppression and induction of apoptosis. It is intriguing that these effects are not restricted to mutant K-ras pancreatic cancer cells, but are also evident in wild-type K-ras BxPC-3 cells. In this Ad.mda-7 plus ROS-inducer combinatorial approach, K-ras protein levels do not change (unpublished data), suggesting a different mechanism of action that is not dependent on downregulation of the level of K-ras protein. Whether ROS treatment induces changes in protein translational profiles of specific mRNAs, including mda-7/IL-24, by a mechanism that is distinct from ablating ras expression is not presently known. Of potential clinical bearing, similar treatments of normal cells do not result in growth suppression or apoptosis, even though these cells produce mda-7/IL-24 mRNA and both intracellular and secreted MDA-7 protein following infection with Ad.mda-7 (Lebedeva et al., 2002; Su et al., 2003) . Figure 6 Ad.mda-7 infection or stable mda-7/IL-24 expression in combination with ROS generators promotes cell death in pancreatic carcinoma cells, which correlate with the downregulation of ERK 1/2 activity. The indicated pancreatic carcinoma cell type, stable mda-7/IL-24 mRNA expressing clone or H-TERT immortalized human fetal astrocytes (PHFA-Im) were infected with 100 pfu/cell of Ad.vec or Ad.mda-7 and untreated or treated with a ROS generator (same doses as in Figure 3 ) as described in Materials and methods. At 24 h after ARS, HPR and NSC addition, cells were lysed and subjected to SDS-PAGE and immunoblotting to determine the phosphorylation (activity) of ERK1/2. (Also presented as a table showing changes in the phosphorylation of ERK 1/2 normalized to total ERK expression in the samples) Figure 7 Therapeutic effect of combined treatment with ARS and Ad.mda-7 on the growth of pancreatic cancer cells in nude mice. Nude athymic mice were injected with PANC-1 cells either untreated or treated as indicated and described in Materials and methods. Tumor measurements were performed 3 weeks after injection. Statistical significance was determined by a Student's ttest, and a P-value of o0.05 is indicated by an asterisk
The mechanism underlying mda-7/IL-24 mRNA translational suppression in pancreatic cancer cells and its extinction following inhibition of mutant K-ras expression or treatment with ROS inducers is not known. It is evident, however, from this and a previous study (Su et al., 2001 ) that a common denominator of both treatment protocols that results in induction of apoptosis is the conversion of untranslated mda-7/IL-24 mRNA into MDA-7 protein, which can be found both within and secreted from pancreatic tumor cells. These findings argue that pancreatic cancer cells retain sensitivity to the apoptosis-promoting activity of mda-7/IL-24, but the efficiency of translation of this message is somehow impeded in both wild type and mutant Kras pancreatic cancer cells. Support for this hypothesis comes from recent studies using a purified GST-MDA-7 fusion protein Yacoub et al., 2003a Yacoub et al., -c, 2004 Sauane et al., 2004) , which selectively induces apoptosis in both types of pancreatic cancer cells . Based on these findings, approaches that can pharmacologically or genetically remedy the mda-7/IL-24 translational block in pancreatic cancer cells, and potentially other tumor cell types, offers promise for enhancing the therapeutic utility of this gene. Additionally, such an approach or the use of pure MDA-7 protein may also find utility in other tumor cell types or in specific tumor-cell variants displaying resistance to adenovirus mediated mda-7/IL-24-induced apoptosis.
ARS and HPR promote apoptosis in a broad spectrum of human tumors, both in vitro and in vivo (Delia et al., 1995; Jing et al., 1999; Hail and Lotan, 2000; Wu et al., 2001; Miller et al., 2002; Simeone et al., 2002; Vuky et al., 2002; Li et al., 2003) , whereas the proapoptotic activity of NSC has not been analysed in similar detail . Mechanistic studies indicate that ROS induction is a prerequisite for proapoptotic activity and emphasize the importance of the intrinsic (mitochondrial) apoptosis pathway in mediating cell killing (Jing et al., 1999; Hail and Lotan, 2000; Wu et al., 2001; Miller et al., 2002; Simeone et al., 2002; Vuky et al., 2002; Li et al., 2003) . These investigations and a number of others document several interesting parallels between how ROS inducers and mda-7/IL-24 kills various tumor cells, including pancreatic tumor cells following ablation of K-ras (Su et al., 2001) or treatment with ARS, HPR or NSC (Delia et al., 1995; Jing et al., 1999; Hail and Lotan, 2000; Wu et al., 2001; Kim et al., 2002; Miller et al., 2002; Simeone et al., 2002; Vuky et al., 2002; Xia et al., 2002; Zou et al., 2002; Lebedeva et al., 2003b; Li et al., 2003) . Apoptosis induced by Ad.mda-7 in 'permissive' prostate, melanoma and malignant glioma cells and in 'resistant' pancreatic cancer cells (simultaneously treated with K-ras antisense phosphorothioate oligonucleotides) results in alterations in the ratio of antiapoptotic (such as Bcl-2 and Bcl-x L ) and proapoptotic (including Bax and Bak) proteins, changes in cell cycle resulting in accumulation of cells in the G 2 /M phase and upregulation in expression of the growth arrest and DNA damage inducible (GADD) gene family (Su et al., 2001 Lebedeva et al., 2002 Lebedeva et al., , 2003a Sarkar et al., 2002b) . In a similar manner, induction of apoptosis by a high dose of ARS (6.25 mM) in MIA PaCa-2 and PANC-1 pancreatic cancer cells results in similar changes, including decreased Bcl-2 and increased Bax expression, cell cycle arrest in the G 2 /M phase and markedly enhanced GADD45 and GADD153 expression (Li et al., 2003) . Correspondingly, treatment of specific cancers with HPR also decreases bcl-2 expression and induces or increases the levels of GADD45 and GADD153 (Delia et al., 1995; Kim et al., 2002; Xia et al., 2002; Zou et al., 2002) . In these contexts, the synergy observed between the ROS-inducers and mda-7/IL-24 culminating in apoptosis in pancreatic cancer cells may proceed by inducing parallel downstream changes that normally lead to mitochondrial-mediated cell death when mda-7/ IL-24 is administered to permissive cancer cells or when the ROS-inducers are used at high concentrations. In addition, in a broad spectrum of permissive human tumor cells, ARS and ionizing radiation also enhance Ad.mda-7 and GST-MDA-7 lethality (Kawabe et al., 2002; Su et al., 2003; Yacoub et al., 2003a Yacoub et al., -c, 2004 Sauane et al., 2004) , indicating that ROS generation can synergize with extant MDA-7 protein to enhance cell death in carcinoma cells.
Studies by several laboratories have demonstrated that Ad.mda-7 lethality is promoted by enhanced p38 MAPK signaling, and in some cells, by ERK1/2 signaling (Kawabe et al., 2002; Yacoub et al., 2003c) . In glioma and lung carcinomas, radiosensitization of cells by Ad.mda-7, which was ROS-dependent, required activation of the JNK1/2 pathway (Kawabe et al., 2002; Sarkar et al., 2002b; Yacoub et al., 2003c) . In pancreatic adenocarcinoma cells, in a cell type dependent manner, the induction of cell death by ROS generating agents correlated with the modulation of discrete cassettes of multiple signaling pathways in different pancreatic tumor cells. In PANC-1, MIA PaCa-2 and BxPC-3 cells, ROS generation, the induction of MDA-7 protein, and cell death correlated with elevated JNK1/2 and p38 MAPK, and, to a lesser extent, reduced ERK1/2 and ERK5 activity. However, in PANC-1 cells, the role of pERK1/2 downregulation in apoptotic signaling is not general, since only the combination of NSC with Ad.mda-7 caused this effect (Table 2c ). In BxPC-3 cells, p38 MAPK activation occurred only in cells treated with ARS plus Ad.mda-7 combination treatment, while loss of ERK5 phosphorylation after Ad.mda-7 and ROS inducer treatment was the most profound in this cell line among the three pancreatic cancer cell lines studied. In summary, signaling pathways differ in the same cell line upon different ROS inducer treatment. Moreover, the effect of the same ROS-inducing reagent on signaling pathways differs in different cell lines (Figures 5 and 6 , Table 2 ). These findings support a mode of action of mda-7/IL-24 in combination with Ad.mda-7 in pancreatic cancer cells involving a systematic disruption of multiple signaling pathways, a process we term 'global signaling dysregulation. ' These findings are all in general agreement with a shift from induction of prosurvival signaling processes in the presence of ROS generators or Ad.mda-7/MDA-7 as single agents to proapoptotic signaling processes when ROS generators are combined with Ad.mda-7/MDA-7 (Dent et al., 1998 . That ROS generators and mda-7 apparently utilize different signaling strategies to cause cell death in three independent pancreatic adenocarcinoma cell lines supporting the concept that induction of cancer cell death by Ad.mda-7/MDA-7 can be initiated by multiple signaling pathways, that is, 'global signaling dysregulation' (Sarkar et al., 2002a; Fisher et al., 2003; Sauane et al., 2003; Lebedeva et al., 2004) . These findings also argue that global a priori predictions of which pathway(s) may promote survival or death in response to Ad.mda-7/MDA-7 in a given pancreatic cancer cell may not be possible. Further studies are required to determine whether inactivation of ERK1/2 and activation of p38 and JNK in PANC-1 and Mia PaCa-2 cells, respectively, and inactivation of ERK1/2 and ERK5 and activation of JNK1/2 in BxPC-3 cells are causal in promoting cell death in these pancreatic cancer cell lines.
In summary, we presently demonstrate that the cytokine mda-7/IL-24 can efficiently kill both mutant and wild-type K-ras pancreatic cancer cells when combined with agents that facilitate the production of ROS. In contrast, similar experimental protocols applied to normal cells do not induce harmful effects. This unique synergy in pancreatic cancer cells correlates with the ability of ROS to relieve the translational block preventing conversion of mda-7/IL-24 mRNA into protein and global alterations in multiple signal transduction pathways that appear to be pancreatic cancer cell specific. Since ROS inducers, specifically ARS and HPR, have now entered the clinical arena and have shown promise, as has Ad.mda-7, this novel combinatorial approach offers potential for translation into an effective therapy for pancreatic cancer, a horrific disease without a currently effective therapy.
Materials and methods

Cell lines, culture conditions and virus infection protocol
MIA PaCa-2, PANC-1 and BxPC-3 pancreatic carcinoma cells were obtained from the American Type Culture Collection (ATCC). Stable clones of PANC-1 and MIA PaCa-2 cells expressing mda-7/IL-24 mRNA were produced by transfection with an mda-7/IL-24 expression vector and selection in hygromycin as described previously . Northern and Western blotting, respectively, confirmed expression of mda-7/IL-24 mRNA in these clones, without detectable protein. An SV-40 T-antigen-immortalized human melanocyte cell line, FM516-SV (Lebedeva et al., 2002) , and an H-TERT-immortalized normal human fetal astrocyte cell line, PHFA-Im , were described previously. All cells were cultured as described (Su et al., 2001) . The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (Su et al., 1998) and plaque purified by standard procedures. Cells were infected with 100 pfu/cell of Ad.mda-7 or Ad.vec and analysed as described (Su et al., 1998; Lebedeva et al., 2002) . ARS and HPR were obtained from Sigma (St Louis, MO, USA) and NSC (dithiophene) was provided by NIH.
RNA isolation and Northern blotting analysis
Total RNA was extracted from cells using the Qiagen RNeasy mini kit according to the manufacturer's protocol and was used for Northern blotting as previously described (Su et al., 1997 (Su et al., , 1999 . Briefly, 15 mg of RNA for each sample was denatured, electrophoresed in 1.2% agarose gel with 3% formaldehyde and transferred onto nylon membranes. The blots were probed with an a-32 P[dCTP] full-length human mda-7 cDNA probe, then stripped and reprobed with an a-32 P[dCTP] human gapdh probe. Following hybridization, the filters were washed and exposed for autoradiography.
MTT viability assays
Cells were seeded in 96-well tissue culture plates (1.5 Â 10 3 cells per well) and treated 24 h later with various agents as described in Results. At indicated time points, medium was removed, and 100 ml of fresh medium containing 0.5 mg/ml MTT was added to each well. After 4 h incubation in 5% CO 2 atmosphere at 371C, equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well. After mixing and complete dissolution of the precipitate, plates were read using BioRad multiplate reader Model 550 at 595 nm (Lebedeva et al., 2000) . Cell viability was assessed as a ratio between an optical densities of treated cells to the untreated cells. A statistical analysis of the results was performed using the Analysis ToolPack provided by Microsoft Excel. A Student two-sample t-test, assuming unequal variances, was used to determine the equality of the means of two samples. The confidence level a was 0.05.
Annexin V binding assays
At the indicated time points after treatment, cells (5 Â 10 5 cells per sample) were trypsinized, washed with complete medium and PBS, resuspended in 500 ml of binding buffer containing 2.5 mM CaCl 2 and stained with FITC-labeled Annexin-V (BD Biosciences, Palo-Alto, CA, USA) and PI for 15 min at room temperature. Flow cytometry was performed immediately after staining .
Preparation of cell extracts and Western blotting analysis
Protein lysates were prepared on ice and protein concentrations were determined as described previously (Lebedeva et al., 2002) . Cell extracts in RIPA buffer were prepared and equal aliquots of proteins were evaluated for MDA-7 and EF-1a protein levels by Western blotting as described (Su et al., 2001 Lebedeva et al., 2003a) . To determine the activities of JNK1/2, p38 MAPK, ERK1/2 and ERK5 phosphoimmunoblotting was performed with corresponding phosphospecific and total antibodies, ratios between the levels of phosphorylated and total kinases were calculated for each treated sample and results were normalized to the above ratio in Ad.vectreated cells as described in Yacoub et al. (2003b) . Antibodies detecting total and phosphorylated forms of JNK and p38 MAPK kinases were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). Antibodies for total ERK1/2 and phosphorylated ERK were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies for total and phosphorylated ERK5 were from Biosource International (Camarillo, CA, USA).
Assessment of ROS production
To determine ROS production, cells (5 Â 10 5 cells per sample) were trypsinized, washed with complete medium and PBS, and stained with 2.5 mM HE in PBS for 30 min at 371C in the dark . Immediately after staining, cells were analysed by flow cytometry (FACScan, Becton-Dickinson, Mountain View, CA, USA). In all cases, cells were gated to exclude cell debris. Red fluorescence was measured in the Fl2 channel. An increase in red fluorescence corresponds to the increased proportions of cells with high ROS content.
Animal studies
Tumorigenicity assays were performed as previously described (Su et al., 1998 (Su et al., , 2001 Madireddi et al., 2000) . Briefly, PANC-1 cells were untreated or treated with ARS (1 mM) and infected with 100 pfu/cell of Ad.vec, Ad.mda-7 alone or in combination with ARS, and 24 h later, 2 Â 10 6 cells were mixed with Matrigel and injected subcutaneously into athymic nude mice. Animals were monitored for tumor formation, and tumor volume was determined and statistical significance was evaluated with the Student's t-test using the computer program SIGMA STAT (Jandel, San Rafael, CA, USA) (Su et al., 1998; Madireddi et al., 2000) .
Statistical analysis
All of the experiments were performed at least three times. Results are expressed as mean7s.e. Statistical comparisons were made using an unpaired two-tailed Student's t-test. A Po0.05 was considered significant. Abbreviations mda-7/IL-24, melanoma differentiation associated gene-7/ interleukin-24; ROS, reactive oxygen species; ARS, arsenic trioxide (A 2 O 3 ); HPR, N-(4-hydroxyphenyl) retinamide; NSC, NCS646240; NAC, N-acetyl-L-cysteine; pfu, plaque-forming units.
